Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2010
10/26/2010US7820193 Anticancer agents; prevent forming blood vessels; removal blockage
10/26/2010US7820178 VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
10/26/2010US7820161 Treatment of autoimmune diseases
10/26/2010US7820157 Retroviral vector comprising nucleotide sequences coding collagen domain for use in wound healing; tissue repair and engineering; regenerative medicine
10/26/2010CA2543650C A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing thesame
10/26/2010CA2449192C Novel nitriles useful as reversible inhibitors of cysteine proteases
10/26/2010CA2422708C 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
10/26/2010CA2418921C Novel composition
10/26/2010CA2412164C Amidine derivatives as selective antagonists of nmda receptors
10/26/2010CA2410594C Heterocyclic aminoalkylpyridine derivatives as psychopharmaceuticals
10/26/2010CA2410201C Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
10/26/2010CA2409698C Neural progenitor cell populations
10/26/2010CA2398707C C1 inhibitor produced in the milk of transgenic mammals
10/26/2010CA2326501C Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
10/26/2010CA2304700C Lipophilic diesters of chelating agents
10/26/2010CA2291138C Transplants for myocardial scars and method and cellular preparations therefor
10/26/2010CA2192928C Benzoheterocyclic derivatives
10/21/2010WO2010121207A1 Methods and compositions related to the interaction of t-cadherin and adiponectin
10/21/2010WO2010120905A2 Novel nano-probes for molecular imaging and targeted therapy of diseases
10/21/2010WO2010120698A1 Vitamin d receptor agonists and uses thereof
10/21/2010WO2010119990A1 Pharmaceutical compositions
10/21/2010WO2010119875A1 Fused pyrrolopyridine derivative
10/21/2010WO2010119700A1 Novel compound having 3-heteroarylpyrimidin-4-(3h)-one structure and pharmaceutical preparation containing same
10/21/2010WO2010119674A1 Pharmaceutical composition for ameliorating and/or preventing leptin resistance, and use thereof
10/21/2010WO2010119306A1 Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
10/21/2010WO2010119161A2 Antiepileptic, hypocholesterolemic and neuroprotective compound
10/21/2010WO2010119050A1 New rac1 inhibitors as potential pharmacological agents for heart failure treatment
10/21/2010WO2010118992A1 Process for preparation of endothelial receptor antagonist (bosentan)
10/21/2010WO2010118968A1 No-donor aspirin derivatives
10/21/2010WO2010118639A1 Amlodipine microsphere agent, production method and use thereof
10/21/2010WO2010099054A3 Soluble guanylate cyclase activators
10/21/2010WO2010077928A3 Flavononol renin inhibitor compounds and methods of use thereof
10/21/2010WO2010077364A3 Stroke-generated angiogenesis enhancers and uses thereof
10/21/2010WO2010077101A3 Novel thiazolidinedione derivative and use thereof
10/21/2010WO2010068866A3 Therapeutic particles suitable for parenteral administration and methods of making and using same
10/21/2010WO2010068056A3 Composition containing glucosamine or glucosamine derivative for preventing or treating hemadostenosis and restenosis
10/21/2010WO2010062122A3 Composition for preventing or treating artherosclerosis
10/21/2010WO2010059967A3 Amide inhibitors of renin
10/21/2010WO2010056985A3 Treatment of proteinopathies using a farnesyl transferase inhibitor
10/21/2010WO2010022177A3 Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
10/21/2010US20100269180 Methods, compositions and transgenic models related to the interaction of t-cadherin and adiponectin
10/21/2010US20100268329 Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease
10/21/2010US20100267829 Pharmaceutical composition comprising low concentrations of environment pollutants
10/21/2010US20100267827 Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
10/21/2010US20100267826 Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists
10/21/2010US20100267822 Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases
10/21/2010US20100267804 Differential expression of micrornas in nonfailing versus failing human hearts
10/21/2010US20100267800 N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses
10/21/2010US20100267799 Orodispersible pharmaceutical composition of perindopril
10/21/2010US20100267798 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
10/21/2010US20100267793 Method of treatment using n3 alkylated benzimidazole derivatives as mek inhibitors
10/21/2010US20100267789 Tablet formulations comprising valsartan
10/21/2010US20100267788 Dual-acting antihypertensive agents
10/21/2010US20100267787 Pharmaceutical Compositions
10/21/2010US20100267786 Dual acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and ne utral endopeptidase (ep) inhibitor
10/21/2010US20100267785 Candesartan cilexetil
10/21/2010US20100267784 Novel 4,5-dihydroisoxazoles with estrogenic activity
10/21/2010US20100267778 Diphenyl ether compound, process for producing the same, and use
10/21/2010US20100267767 Nuclear receptor binding agents
10/21/2010US20100267765 Pharmaceutical Compositions and Methods for CCR5 Antagonists
10/21/2010US20100267761 7-Azaindole Derivatives as Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors
10/21/2010US20100267754 Integrin expression inhibitor
10/21/2010US20100267752 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
10/21/2010US20100267749 Trisubstituted furopyrimidines and use thereof
10/21/2010US20100267748 HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
10/21/2010US20100267745 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents
10/21/2010US20100267741 Compounds, Compositions and Methods Comprising Pyrazole Derivatives
10/21/2010US20100267738 Novel amide and amidine derivatives and uses thereof
10/21/2010US20100267736 Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
10/21/2010US20100267735 Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
10/21/2010US20100267725 Compounds, Compositions and Methods Comprising 4N-Substituted Triazole Derivatives
10/21/2010US20100267722 Novel proline derivatives
10/21/2010US20100267721 Heterocyclic H3 Antagonists
10/21/2010US20100267717 Novel Heterocyclic NF-kB Inhibitors
10/21/2010US20100267713 4,4-disubstituted piperidines
10/21/2010US20100267711 Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof
10/21/2010US20100267710 N3 alkylated benzimidazole derivatives as mek inhibitors
10/21/2010US20100267706 Compounds, Compositions and Methods Comprising Pyridazine Derivatives
10/21/2010US20100267696 Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors
10/21/2010US20100267693 Orodispersible pharmaceutical composition of ivabradine
10/21/2010US20100267690 Tricyclic guanidine derivatives as sodium-proton exchange inhibitors
10/21/2010US20100267689 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
10/21/2010US20100267688 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
10/21/2010US20100267685 Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones
10/21/2010US20100267675 Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators
10/21/2010US20100267671 Compositions and methods for apoptosis modulators
10/21/2010US20100267669 Heterocyclic cetp inhibitors
10/21/2010US20100267668 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2
10/21/2010US20100267667 Telomerase activating compounds and methods of use thereof
10/21/2010US20100267649 Vascular adhesion molecules and modulation of their function
10/21/2010US20100267633 N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators
10/21/2010US20100267631 Apolipoprotein a-i mimics
10/21/2010US20100267620 Methods for slowing senescence and treating and preventing diseases associated with senescence
10/21/2010US20100267619 Methods and Compositions for Treatment of Atherosclerosis
10/21/2010US20100267618 Methods for treating congestive heart failure
10/21/2010US20100267612 Sustained release composition containing sdf-1
10/21/2010US20100267608 Modifications of cupredoxin derived peptides and methods of use thereof
10/21/2010US20100267046 Isoform-selective inhibitor and activators of pde3 cyclic nucleotide phosphodiesterases
10/21/2010US20100266673 Compositions and methods for the delivery of nitric oxide
10/21/2010US20100266659 Implantable devices formed on non-fouling methacrylate or acrylate polymers
1 ... 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 ... 1595